Skip to main content
SpringerLink
Log in

Treatment of Secondary Progressive Multiple Sclerosis

Current Recommendations and Future Prospects

  • Disease Management
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Disease progression and advancing disability will supervene in the majority of multiple sclerosis patients who are followed over the long-term. This process can begin insidiously from the onset of the disease (primary progression) or after one or more clinical flares (secondary progression). The factors which lead to progression of disability are incompletely understood.

The progressive forms of multiple sclerosis have been remarkably resistant to treatment. The legacy of heroic immunosuppression as a treatment for the disease progression has been modest indeed although there is some recent enthusiasm for immunosuppression with agents like mitoxantrone. In the last decade, the treatment of relapsing forms of multiple sclerosis has been revitalised by the interferons and glatiramer acetate. The robust treatment effect on the magnetic resonance imaging burden of the disease and the modest treatment effect in the suppression of clinical attacks have raised hopes that these agents might stall the disease in its progressive phase. Recent clinical trials with the interferons are indeed showing promise for modest clinical efficacy in patients selected for treatment on the basis of chronic progression.

Given the weakness of the current treatment, the essence of disease management remains the handling of the complications of the disease. The management of bladder disturbances, spasticity, pain, depression, emotional lability, paroxysmal disorders, fatigue and heat intolerance, tremor and sexual dysfunction is reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hashimoto LL, Mak TW, Ebers GC. T cell receptor alpha chain polymorphisms in multiple sclerosis. J Neuroimmunol 1992; 40: 41–8

    Article  PubMed  CAS  Google Scholar 

  2. Olsson T, Zhi WW, Hojeberg B, et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest 1990; 86: 981–5

    Article  PubMed  CAS  Google Scholar 

  3. Panitch HS, Hirsch RL, Haley AS, et al. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; I: 893–5

    Article  Google Scholar 

  4. Ebers GC. Oligoclonal banding in MS. Ann NY Acad Sci 1984; 436: 206–12

    Article  PubMed  CAS  Google Scholar 

  5. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998 Jan 29; 338(5): 278–85

    Article  PubMed  CAS  Google Scholar 

  6. Ebers GC. Genetics and multiple sclerosis: an overview. Ann Neurol 1994; 36 Suppl: S12–4

    Article  PubMed  Google Scholar 

  7. Ebers GC, Bulman DE, Sadovnick AD, et al. A population-based study of multiple sclerosis in twins. N Engl J Med 1986; 315: 1638–42

    Article  PubMed  CAS  Google Scholar 

  8. Ebers GC, Paty DW, Stiller CR, et al. HLA-typing in multiple sclerosis sibling pairs. Lancet 1982; II: 88–90

    Article  Google Scholar 

  9. Brassat D, Azais-Vuillemin C, Yaouanq J, et al. Familial factors influence disability in MS multiplex families. French Multiple Sclerosis Genetics Group. Neurology 1999 May 12; 52(8): 1632–6

    Article  PubMed  CAS  Google Scholar 

  10. Ebers GC, Sadovnick AD. The geographic distribution of multiple sclerosis: a review. Neuroepidemiology 1993; 12: 1–5

    Article  PubMed  CAS  Google Scholar 

  11. Kastrukoff LF, Rice GPA. In: Paty DW, Ebers GC, editors. Multiple sclerosis. Vol. 50: Contemporary neurology series. Philadelphia (PA): F.A. Davis, 1997: 370–82

    Google Scholar 

  12. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112: 133–46

    Article  PubMed  Google Scholar 

  13. Kremenchutzky M, Lee D, Rice GPA, et al. Primary progressive multiple sclerosis. Brain MRI findings. Neurology 1997 Jun 17; 52: A358

    Google Scholar 

  14. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989; 112: 1419–28

    Article  PubMed  Google Scholar 

  15. Filippi M, Horsfield MA, Morrissey S, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994; 44: 635–41

    Article  PubMed  CAS  Google Scholar 

  16. Cottrell DA, Rice GPA, Hader W, et al. The natural history of multiple sclerosis: a geographically-based study: 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999; 122 (Pt 4): 625–39

    Article  PubMed  Google Scholar 

  17. Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. Brain 1999; 122 (Pt 4): 641–7

    Article  PubMed  Google Scholar 

  18. Kurtzke JF. Neurologic impairment in multiple sclerosis and the disability status scale. Acta Neurol Scand 1970; 46(4): 493–512

    Article  PubMed  CAS  Google Scholar 

  19. Ebers GC. Treatment of multiple sclerosis. Lancet 1994; 343: 275–9

    Article  PubMed  CAS  Google Scholar 

  20. Rudick R, Antel J, Confraveux S, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997; 42: 379–82

    Article  PubMed  CAS  Google Scholar 

  21. Paty DW, McFarland H. Magnetic resonance techniques to monitor the long term evolution of multiple sclerosis pathology and to monitor definitive clinical trials [review]. J Neurol Neurosurg Psychiatry 1998 May; 64Suppl. 1: S47–51

    PubMed  Google Scholar 

  22. Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326:581–8

    Article  PubMed  CAS  Google Scholar 

  23. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 1993; 329: 1764–9

    Article  PubMed  CAS  Google Scholar 

  24. Alam SM, Kyriakides T, Lawden M, et al. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993; 56: 1219–20

    Article  PubMed  CAS  Google Scholar 

  25. Barnes D, Hughes RA, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997 Mar 29; 349(9056): 902–6

    Article  PubMed  CAS  Google Scholar 

  26. Metz LM, Sabuda D, Enns R, et al. Safety and tolerability of high dose oral prednisone in the treatment of multiple sclerosis [abstract]. Neurology 1998; 50: A63

    Google Scholar 

  27. Sellebjerg F, Nielsen HS, Frederiksen JL, et al. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999 Apr 22; 52(7): 1479–84

    Article  PubMed  CAS  Google Scholar 

  28. Miller DH, Thompson AJ, Morrissey SP, et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. Neurol Neurosurg Psychiatry 1992; 55: 450–3

    Article  CAS  Google Scholar 

  29. Oliveri RL, Valentino P, Russo C, et al. A randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 1998 Jun; 50(6): 1833–6

    Article  PubMed  CAS  Google Scholar 

  30. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987 May; 50(5): 511–6

    Article  PubMed  CAS  Google Scholar 

  31. Weinshenker BG, Sibley WA. Natural history and treatment of multiple sclerosis. Curr Opin Neurol Neurosurg 1992; 5: 203–11

    PubMed  CAS  Google Scholar 

  32. Goodkin DE, Bailly RC, Teetzen MI, et al. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 1991; 41: 20–5

    Article  PubMed  CAS  Google Scholar 

  33. Cavazzuti M, Merelli E, Tassone G, et al. Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment. A retrospective study. Eur Neurol 1997; 38(4): 284–90

    Article  PubMed  CAS  Google Scholar 

  34. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm Res 1999 Mar; 16(3): 342–9

    Article  PubMed  CAS  Google Scholar 

  35. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The rFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 655–61

  36. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta 1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285–94

    Article  PubMed  CAS  Google Scholar 

  37. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998 Nov 7; 352(9139): 1498–504

    Article  Google Scholar 

  38. Rice GPA, Ebers GC. Interferons and disease progression. Arch Neurol 1998 Dec; 55(12): 1578–80

    Article  PubMed  CAS  Google Scholar 

  39. Rice GP, Paszner B, Oger J, et al. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999 Apr 12; 52(6): 1277–9

    Article  PubMed  CAS  Google Scholar 

  40. Panitch H, Francis G, Oral Myelin Study Group. Clinical results of a phase three study of oral myelin in relapsing-remitting MS. Ann Neurol 1997; 42: 459

    Google Scholar 

  41. Johnson KP, Brooks BR. Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis; results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268–76

    Article  PubMed  CAS  Google Scholar 

  42. Comi G, Filippi M, Copaxone MRI Study Group. The effect of glatiramer acetate on disease activity as measured by cerebral MRI in patients with relapsing remitting multiple sclerosis: a multi-center, randomized, double-blind, placebo-controlled study extended by open label treatment [abstract]. Neurology 1999; 52: A289

    Google Scholar 

  43. Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998 May; 50(5): 1273–81

    Article  PubMed  CAS  Google Scholar 

  44. Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997 Mar 1; 349(9052): 589–93

    Article  PubMed  CAS  Google Scholar 

  45. Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998 Feb; 50: 398–402

    Article  PubMed  CAS  Google Scholar 

  46. Lycke J, Svennerholm B, Hjelmquist E, et al. Acyclovir treatment of relapsing-remitting multiple sclerosis. Arandomized, placebo-controlled, double-blind study. J Neurol 1996 Mar; 243(3): 214–4

    Article  PubMed  CAS  Google Scholar 

  47. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338: 1051–55

    Article  PubMed  CAS  Google Scholar 

  48. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis; a randomized, three arm study of high dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 1983; 308: 183–80

    Article  Google Scholar 

  49. Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337: 441–6

    Google Scholar 

  50. Likosky WH, Fireman B, Elmore R, et al. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry 1991; 54: 1055–60

    Article  PubMed  CAS  Google Scholar 

  51. The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomised double-blinded, placebo-controlled clinical trial. Ann Neurol 1990; 27: 591–605

    Article  Google Scholar 

  52. Currier RD, Haerer AF, Meydrech EF. Low dose oral methotrexate treatment of multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry 1993; 56: 1217–8

    Article  PubMed  CAS  Google Scholar 

  53. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995 Jan; 37(1): 30–40

    Article  PubMed  CAS  Google Scholar 

  54. Cook SD, Devereux C, Troiano R, et al. Effect of total lymphoid irradiation in chronic progressive MS. Lancet 1986; I: 1405–9

    Article  Google Scholar 

  55. Rice GPA, Cladribine Clinical Study Group, Filippi M, Comi G, Cladribine MSI study group. Therapeutic effect of Mylinax (cladribine) on disease activity and burden in progressive multiple sclerosis. Neurology. In press

  56. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997 Feb; 62(2): 112–8

    Article  PubMed  CAS  Google Scholar 

  57. Noseworthy JH, Hopkins MB, Vandervoort MK, et al. An opentrial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993; 43: 1401–6

    Article  PubMed  CAS  Google Scholar 

  58. Bornstein MB, Miler A, Slagle S. A placebo-controlled, double blind randomized, two center pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991; 41: 533–9

    Article  PubMed  CAS  Google Scholar 

  59. Goodkin DE, Kinkel RP, Weinstock-Guttman B, et al. A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998 Jul; 51(1): 239–45

    Article  PubMed  CAS  Google Scholar 

  60. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998 Nov 7; 352(9139): 1491–7

    Article  Google Scholar 

  61. Paty DW, SPMS Interferon Beta 1A Study Group. Results of the 3 year double-blind, placebo-controlled study of interferon beta 1A (Rebif) in secondary progressive MS. J Neurol 1999; 246: 1–15

    Google Scholar 

  62. Burt RK, Burns WH, Miller SD. Bone marrow transplantation for multiple sclerosis: returning to Pandora’s box. Immunol Today 1997 Dec; 18(12): 559–61

    Article  PubMed  CAS  Google Scholar 

  63. Jeffery D. Alshami E. Allogenic bone marrow transplantation in multiple sclerosis [abstract]. Neurology 1998; 50: A147

    Google Scholar 

  64. Hinson JL, Boone TB. Urodynamics and multiple sclerosis. Urol Clin North Am 1996 Aug; 23(3): 475–81

    Article  PubMed  CAS  Google Scholar 

  65. De Ridder D, Chandiramani V, Dasgupta P, et al. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term followup. Urology 1997 Dec; 158(6): 2087–92

    Article  Google Scholar 

  66. Rice GPA. Pharmacotherapy of spasticity — some theoretical and practical considerations. Can J Neurol Sci 1987; 14: 510–2

    PubMed  CAS  Google Scholar 

  67. Becker WJ, Harris CJ, Long ML, et al. Long-term intrathecal baclofen therapy in patients with intractable spasticity. Can J Neurol Sci 1995 Aug; 22(3): 208–17

    PubMed  CAS  Google Scholar 

  68. Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis [see comments]. Neurology 1988; 38: 1830–4

    Article  PubMed  CAS  Google Scholar 

  69. McCleane G. Lamotrigine can reduce neurogenic pain associated with multiple sclerosis. Clin J Pain 1998 Sep; 14(3): 269–70

    Article  PubMed  CAS  Google Scholar 

  70. Houtchens MK, Richert JR, Sami A, et al. Open label gabapentin treatment for pain in multiple sclerosis. Mult Scler 1997 Aug; 3(4): 250–3

    Article  PubMed  CAS  Google Scholar 

  71. Feinstein A, Feinstein K, Gray T, et al. Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol 1997 Sep; 54(9): 1116–21

    Article  PubMed  CAS  Google Scholar 

  72. Rice GPA. Management of paroxysmal symptoms in multiple sclerosis. Proceedings of the MS Forum Modern Management Workshop, Professional Postgraduate Services Europe Ltd; 1994 Apr; Worming, UK

  73. Solaro C, Lunardi GL, Capello E, et al. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis. Neurology 1998 Aug; 51(2): 609–11

    Article  PubMed  CAS  Google Scholar 

  74. Linet OI, Ogring FG, Alprostadil Study Group. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334: 873–7

    Article  PubMed  CAS  Google Scholar 

  75. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998 May 14; 338(20): 1397–404

    Article  PubMed  CAS  Google Scholar 

  76. Krupp LB, Coyle PK, Doscher C, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995 Nov; 45(11): 1956–61

    Article  PubMed  CAS  Google Scholar 

  77. Weinshenker BG, Penman M, Bass B, et al. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992 Aug; 42(8): 1468–71

    Article  PubMed  CAS  Google Scholar 

  78. Sheean GL, Murray NM, Rothwell JC, et al. An open-labelled clinical and electrophysiological study of 3,4-diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain 1998 May; 121 (Pt 5): 967–75

    Article  PubMed  Google Scholar 

  79. Sandyk R. Successful treatment of cerebellar tremor with clonazepam. Clin Pharm 1985 Nov; 4(6): 615

    PubMed  CAS  Google Scholar 

  80. Rice GP, Lesaux J, Vandervoort P, et al. Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. J Neurol Neurosurg Psychiatry 1997 Mar; 62(3): 282–4

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Multiple Sclerosis Clinical Trials, London, Ontario, Canada, N6A 5A5

    George P.A. Rice

Authors
  1. George P.A. Rice
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George P.A. Rice.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rice, G.P. Treatment of Secondary Progressive Multiple Sclerosis. BioDrugs 12, 267–277 (1999). https://doi.org/10.2165/00063030-199912040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199912040-00004

Keywords

Search

Navigation